Table 4.
Current clinical studies of RNA-mediated immunotherapy for the treatment of cancer
| Targeting Cell | RNAs Encoding | Cancer Types | Status | ClinicalTrials.gov Identifier Number |
|---|---|---|---|---|
| T cells | MET scFv CAR | Malignant Melanoma, Breast Cancer | Early Phase 1 Recruiting | NCT03060356 |
| cMet CAR | Metastatic Breast Cancer; Triple Negative Breast Cancer | Phase 1 Completed | NCT01837602 | |
| Chimeric anti-mesothelin immunoreceptor SS1 | Pancreatic Cancer | Phase 1 Completed | NCT01897415 | |
| DCs | TAAs: NY-ESO-1, MAGEC1, MAGEC2, 5 T4, Survivin, and MUC1 | Lung Cancer | Phase 2 Recruiting | NCT03164772 |
| TAAs: PSA, PSCA, PSMA, STEAP1, PAP and MUC1 | Prostate Carcinoma | Phase 2 Completed | NCT02140138 | |
| Neo-Ag | Melanoma | Active No Recruiting |
NCT02035956 | |
| Neo-Ag | Solid tumor | Phase 1 Recruiting | NCT03313778 | |
| Neo-Ag | Melanoma; Colon Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Hepatocellular Cancer | Phase 2 Completed | NCT03480152 | |
| Three variant RNAs; p53, and Neo-Ag based on NGS screening | Breast Cancer (Triple Negative Breast Cancer) | Phase 1 Recruiting | NCT02316457 | |
| Carcinoembryonic antigen RNA | Colorectal Cancer; Metastatic Cancer | Phase 2 Completed | NCT00003433 | |
| Prostate specific antigen (PSA) | Prostate Cancer | Phase 2 Completed | NCT00004211 | |
| Carcinoembryonic antigen | Breast Cancer; Colorectal Cancer; Extrahepatic Bile Duct Cancer | Phase 1 Completed | NCT00004604 | |
| Total tumor RNA | Kidney Cancer | Phase 1 Completed | NCT00005816 | |
| Autologous tumor RNA | Melanoma | Phase 3 Recruiting | NCT01983748 | |
| TAAs: NYESO-1, MAGE-A3, tyrosinase, and TPTE | Melanoma | Phase 1 Recruiting | NCT02410733 | |
| siRNA: LMP2, LMP7, and MECL1; mRNA: MART-1, tyrosinase, gp100, and MAGE-3 | Melanoma | Phase 1 Completed | NCT00672542 | |
| Melan-A, Mage-A1, Mage-A3, Survivin, GP100 and Tyrosinase | Malignant Melanoma | Phase 1/2 Completed | NCT00204516 | |
| pp65-flLAMP | Glioblastoma | Active No recruiting | NCT03615404 |